Fulcrum Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Form 8-K reports cover operating results, financial condition, Regulation FD corporate presentations, clinical updates for pociredir in sickle cell disease, and material agreements, including license arrangements tied to development programs.
Proxy materials disclose board and governance matters, executive compensation, equity awards, shareholder voting items, and related ownership information. The filing record also documents capital-structure items such as common stock and inducement equity plans alongside public-company disclosures tied to drug development programs and collaboration agreements.
Fulcrum Therapeutics reported a larger full-year 2025 net loss of $74.9 million, compared with $9.7 million in 2024, as it invested in its sickle cell disease program while collaboration revenue fell away. Cash, cash equivalents, and marketable securities rose to $352.3 million as of December 31, 2025, helped by $164.2 million of net proceeds from a December equity offering, giving projected cash runway into 2029.
Clinically, the company announced positive 12-week results from the 20 mg cohort (n=12) of its Phase 1b PIONEER trial of pociredir in sickle cell disease, with mean fetal hemoglobin increasing by 12.2% from 7.1% to 19.3% and improvements in markers of hemolysis and anemia. Pociredir was generally well tolerated with no treatment-related serious adverse events reported at the December 23, 2025 data cutoff. Fulcrum plans an open-label extension study and, pending FDA feedback, aims to start a potential registration-enabling trial in the second half of 2026 while discontinuing its bone marrow failure syndromes program.
RA Capital Management and related parties reported a significant stake in Fulcrum Therapeutics, Inc. through an amended Schedule 13G. As of December 31, 2025, the group is deemed to beneficially own 6,649,973 shares of common stock, representing 9.99% of the company.
The RA Capital Healthcare Fund directly holds 6,053,960 shares and pre-funded warrants initially exercisable for up to 8,500,000 shares. A "Beneficial Ownership Blocker" in the warrants limits exercise so that, together with affiliates, RA Capital cannot exceed 9.99% ownership, which currently caps exercisable warrant shares at 596,013.
The filing notes that voting and investment authority over the fund’s holdings has been delegated to RA Capital and that the securities were not acquired to change or influence control of Fulcrum Therapeutics.
Fulcrum Therapeutics, Inc. director Robert J. Gould sold 15,000 shares of common stock on January 2, 2026 under a Rule 10b5-1 trading plan adopted on August 1, 2025. The weighted average sale price was $10.8726, with individual trades between $10.60 and $11.33.
After these transactions, Gould beneficially owned 469,864 shares of Fulcrum Therapeutics common stock. This amended report updates the previously reported weighted average sale price from $11.8726 to $10.8726.
Fulcrum Therapeutics reported an equity award to its Chief Financial Officer, Alan Musso. On February 2, 2026, he received a stock option to purchase 170,000 shares of common stock at an exercise price of $10.72 per share. Following this grant, he beneficially owns 170,000 derivative securities tied to company stock.
The option is scheduled to vest in equal quarterly installments over four years, beginning on January 1, 2026, and each vesting date requires his continued service. This type of award aligns the CFO’s potential compensation with future stock performance over a multi‑year period.
Fulcrum Therapeutics’ Chief Legal Officer receives new stock option grant. On February 2, 2026, Curtis Gale Oltmans was granted options to purchase 170,000 shares of Fulcrum Therapeutics common stock at an exercise price of $10.72 per share, expiring February 1, 2036.
The options are scheduled to vest in equal quarterly installments over four years, beginning on a vesting commencement date of January 1, 2026, and require his continued service with the company on each vesting date.
Fulcrum Therapeutics director Robert J. Gould reported an automatic stock sale under a pre-set trading plan. On 02/02/2026, he sold 15,000 shares of Fulcrum Therapeutics common stock at a weighted average price of $10.7238 per share, coded as an open market sale.
The transaction was executed pursuant to a Rule 10b5-1 trading plan that he adopted on August 1, 2025, which allows pre-arranged trades. After this sale, Gould beneficially owned 454,864 shares of Fulcrum Therapeutics common stock in direct ownership.
Fulcrum Therapeutics, Inc. reported a stock option grant to its Principal Accounting Officer, Greg Tourangeau. On February 2, 2026, he received a stock option (right to buy) covering 57,000 shares of common stock at an exercise price of $10.72 per share.
The option is scheduled to vest in equal quarterly installments over four years, beginning on the vesting commencement date of January 1, 2026, contingent on his continued service on each vesting date. Following this grant, he beneficially owns 57,000 derivative securities directly.
Fulcrum Therapeutics, Inc. reported a new equity award to its President and Chief Executive Officer, Alex Sapir. On February 2, 2026, Sapir received a stock option to buy 650,000 shares of Fulcrum common stock at an exercise price of $10.72 per share.
The option is scheduled to vest in equal quarterly installments over four years, beginning on the vesting commencement date of January 1, 2026, and depends on Sapir’s continued service on each vesting date. Following this grant, Sapir beneficially owns 650,000 derivative securities directly.
Fulcrum Therapeutics, Inc. reported a preliminary estimate of approximately $352.3 million in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is based on management’s estimates, is unaudited, and may change as year-end financial closing procedures are completed.
The company also released an updated corporate presentation with business and strategic updates, which it plans to use in investor meetings, including a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is available via webcast and as an exhibit to this report.
Fulcrum Therapeutics director Robert J. Gould reported a planned sale of company stock. On January 2, 2026, he sold 15,000 shares of Fulcrum Therapeutics common stock at a weighted average price of $11.8726 per share, with individual trade prices ranging from $10.60 to $11.33. These transactions were carried out under a Rule 10b5-1 trading plan that he adopted on August 1, 2025. After this sale, he beneficially owned 469,864 shares of Fulcrum Therapeutics common stock, held directly.